Novartis

News

US/EU regulators start review of Biogen's high-dose Spinraza

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?

News

New data could widen use of Novartis' SMA therapy Zolgensma

Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.

News

Novartis sheds MorphoSys staff, sites after pelabresib delay

Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.

News

ICER identifies new crop of 'unsupported' drug price rises

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

Oncology

Can CAR-T first movers keep pace in a rapidly evolving marke...

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.

News

Novartis bid to block generic Entresto in US suffers setback

An appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic of its heart failure blockbuster Entresto.

US/EU regulators start review of Biogen's high-dose Spinraza

New data could widen use of Novartis' SMA therapy Zolgensma

Novartis sheds MorphoSys staff, sites after pelabresib delay

ICER identifies new crop of 'unsupported' drug price rises

Can CAR-T first movers keep pace in a rapidly evolving marke...

Novartis bid to block generic Entresto in US suffers setback

Gilead, MSD share data on once-weekly oral HIV treatment

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks